MRI, PET Scan and Pharmaceutical - Diagnostic Imaging Brief

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

MRI

PET Scan

Pharmaceutical

Quibim drives into U.S. market on $50M investment

AuntMinnie

JANUARY 27, 2025

Quibim has closed a $50 million series A financing round to support strategic collaborations with hospitals and pharmaceutical companies in the U.S. The company has been developing human digital twin technology at the organ and lesion level, as well as foundational AI models designed to extract actionable insights from MRI, CT, and PET scans.

PET Scan

PET Scan Pharmaceutical Hospital MRI

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Imaging Technology

OCTOBER 20, 2023

announced a research collaboration agreement with the Alzheimer’s Disease Neuroimaging Initiative 4, ADNI4, on the use of Meilleur’s [F-18]NAV-4694, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status amyloid plaque in the brain.

Disease

Disease PET Scan Pharmaceutical Imaging

Quibim drives into U.S. market on $50M investment

Meilleur Technologies Inc. Announces Use of the Next-Generation Amyloid PET Imaging Biomarker, NAV-4694, in the Alzheimer’s Disease Neuroimaging Initiative 4 (ADNI4)

Stay Connected